Literature DB >> 1495798

Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study.

B M Glaser1, R G Michels, B D Kuppermann, R N Sjaarda, R A Pena.   

Abstract

BACKGROUND: Full-thickness macular holes generally cause a significant reduction in visual acuity, due in part to a rim of surrounding neurosensory retinal detachment and retinal thickening. Recent studies have suggested that flattening of this narrow rim of neurosensory detachment can result in improved visual acuity. However, the ability to flatten the neurosensory detachment is limited using current surgical techniques.
METHODS: Transforming growth factor-beta 2 (TGF-beta 2) is a recently discovered potent stimulator of wound healing. The authors, therefore, performed a prospective randomized study of 60 patients to determine if the local application of TGF-beta 2 to the edge of the macular hole can reproducibly induce flattening of the surrounding neurosensory detachment. The results of a study designed to determine the effect of a pars plana vitrectomy, fluid-gas exchange, and intravitreal instillation of TGF-beta 2 in eyes with a full-thickness macular hole and reduced visual acuity are reported.
RESULTS: After treatment, visual acuity improved 2 lines or more in 5 of 11 eyes treated with 70 ng, in 4 of 12 eyes treated with 330 ng, and in 10 of 11 eyes treated with 1330 ng of TGF-beta 2. In some eyes, hyaluronic acid was added. In these cases, visual acuity improved 2 lines or more in 0 of 9 eyes treated with 70 ng TGF-beta 2, in 2 of 8 eyes treated with 330 ng, and in 4 of 9 eyes treated with 1330 ng.
CONCLUSION: Logistic regression analysis demonstrated a statistically significant beneficial effect of TGF-beta 2 on visual improvement (P = 0.003).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1495798     DOI: 10.1016/s0161-6420(92)31837-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  29 in total

Review 1.  Idiopathic full thickness macular hole: natural history and pathogenesis.

Authors:  E Ezra
Journal:  Br J Ophthalmol       Date:  2001-01       Impact factor: 4.638

2.  Macular hole and myopic refraction.

Authors:  H Kobayashi; K Kobayashi; S Okinami
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

3.  Late reopening of successfully treated macular holes.

Authors:  M Paques; P Massin; P Y Santiago; A C Spielmann; J F Le Gargasson; A Gaudric
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

Review 4.  [Macular hole. Survey and relevant surgical concepts].

Authors:  S Dithmar
Journal:  Ophthalmologe       Date:  2005-02       Impact factor: 1.059

5.  Fundus autofluorescence in patients with macular holes imaged with a laser scanning ophthalmoscope.

Authors:  A von Rückmann; F W Fitzke; Z J Gregor
Journal:  Br J Ophthalmol       Date:  1998-04       Impact factor: 4.638

6.  Indocyanine green assisted retinal internal limiting membrane removal in stage 3 or 4 macular hole surgery.

Authors:  A K H Kwok; T Y Y Lai; W Man-Chan; D C F Woo
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

7.  Objective morphological assessment of macular hole surgery by scanning laser tomography.

Authors:  C Hudson; S J Charles; J G Flanagan; A K Brahma; G S Turner; D McLeod
Journal:  Br J Ophthalmol       Date:  1997-02       Impact factor: 4.638

8.  Macular holes: migratory gaps and vitreous as obstacles to glial closure.

Authors:  H D Schubert; K Kuang; F Kang; M W Head; J Fischbarg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-08       Impact factor: 3.117

9.  Natural outcomes of stage 1, 2, 3, and 4 idiopathic macular holes.

Authors:  T Hikichi; A Yoshida; J Akiba; C L Trempe
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

10.  Transforming growth factor-beta type-II receptor signalling: intrinsic/associated casein kinase activity, receptor interactions and functional effects of blocking antibodies.

Authors:  F L Hall; P D Benya; S R Padilla; D Carbonaro-Hall; R Williams; S Buckley; D Warburton
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.